Lipid Licensing
Access to formulation expertise and proprietary lipid library to streamline drug development
Overview
Safe and effective delivery of mRNA into target cells offers promising therapeutic possibilities. Ionizable lipid-based nanoparticles represent one of the most advanced nonviral vectors for efficient delivery of nucleic acids.
Ionizable lipid design can influence LNP encapsulation efficiency, biodistribution, and therapeutic effects. Fujifilm has designed and characterized a wide array of lipid molecules to accelerate synthesis and empower advanced research and drug development.
Lipid Library
Ionizable Lipids
Ionizable lipids remain neutral at physiological pH and are protonated in acidic conditions. As key components of LNPs, ionizable lipids promote membrane destabilization and facilitate endosomal escape to improve biocompatibility and reduce toxicity.
Learn more about Fujifilm’s CDMO services for LNP formulation development using proprietary ionizable lipids.
Fujifilm has designed and characterized over 500 different ionizable lipids, many of which exceed benchmarks in in vivo mRNA delivery studies.
As we continue to build and expand our lipid library, we offer CDMO services and out-licensing to LNP formulation development partners.
Proprietary Ionizable Lipids
These candidate lipids show improved efficiency and biodistribution and comparable safety compared to commercially available LNPs in various application studies.
Application Studies
Type-A lipids
Prophylactic immunization with Fujifilm Type-A LNP induces anti-tumor immunity
C57BL/6J mice (N=8 per group) were treated with OVA mRNA (TriLink, CleanCap®) encapsulated in FL-0445 via IM injection weekly for 3 weeks (Day -21, -14, -7), positive control (OVA protein/adjuvant mixture) via SQ injection weekly for 3 weeks (Day -21, -14, -7), or vehicle. Tumor (4 × 105 E.G7-OVA cells) was implanted SQ on Day 0.
Tumor volume and percentage of tumor-free mice post implant were comparable to positive control levels.
Type-B lipids
Fujifilm LNPs induce higher protein expression and improve PK profiles in nonhuman primates
Cynomolgus monkey (male, 4 y, N=2) were treated with human erythropoietin (hEPO) mRNA encapsulated in Lipid-5, FL-0207T, or FL-0179T (0.2 mg/kg, 1 h, IV infusion).
Fujifilm’s FL-0207T and FL-0179T LNPs induced higher hEPO expression due, at least in part, to improved circulation times.
Type-B lipids
No hepatotoxicity concerns were observed with Fujifilm LNPs
SD rats (female, 6 wks, N=3) were treated with a single dose of hEPO mRNA encapsulated in Lipid-5, FL-0207T, FL-0179T (1 mg/kg, IV infusion), or vehicle.
No significant increases in AST and ALT — markers of hepatotoxicity — were observed.
Type-D lipids
Fujifilm LNPs deliver pDNA and induce IgG production
Rabbits (N=2) were treated with LNP-encapsulated pDNA (FL-1923T, 0.2 mg/head, IM and ID) or pDNA/adjuvant mixture.
Rabbits treated with Fujifilm LNPs expressed antigen-specific IgG.
Ready-to-use LNP for ex-vivo gene editing in T cells
Fujifilm LNPs show higher endogenous T cell receptor (TCR) knockout efficiency in activated T cells than benchmark.
This ready-to-use LNP formulation is available to customers.
Efficient transfection in primary human T cells cultured ex vivo
Fujifilm has identified LNP formulations that exhibit both improved cell proliferation and performance beyond benchmark LNP when transfected into primary T cells.
